Staff Publications

Staff Publications

  • external user (warningwarning)
  • Log in as
  • language uk
  • About

    'Staff publications' is the digital repository of Wageningen University & Research

    'Staff publications' contains references to publications authored by Wageningen University staff from 1976 onward.

    Publications authored by the staff of the Research Institutes are available from 1995 onwards.

    Full text documents are added when available. The database is updated daily and currently holds about 240,000 items, of which 72,000 in open access.

    We have a manual that explains all the features 

Record number 541482
Title Antibiotic research and development: business as usual?
Author(s) Harbarth, S.; Theuretzbacher, U.; Hackett, J.; Adriaenssens, N.; Anderson, J.; Antonisse, A.; Ardal, C.; Baillon-Plot, N.; Baraldi, E.; Bhatti, T.; Bradshaw, D.; Brown, N.; Carmeli, Y.; Cars, O.; Charbonneau, C.; Cheng, S.; Ciabuschi, F.; Cirino, J.; Clift, C.; Colson, A.; Dane, A.; De-Lima, N.; Dooa, M.; Drabik, D.; Eisenstein, B.; Farquhar, R.; Fidan, D.; Galli, F.; Gilchrist, K.; Gilman, S.; Goeschl, T.; Goodall, J.; Goossens, H.; Gouglas, D.; Guise, T.; Gyssens, I.; Hallerback, P.; Heymann, D.; Hoffman, S.; Howell, J.; Hulscher, M.; Hunt, T.; Huttner, B.; Jantarada, F.; Lindgren, E.; Nolet, B.; Schouten, J.; Vink, P.; Wesseler, J.
Source Journal of Antimicrobial Chemotherapy 70 (2015)6. - ISSN 0305-7453 - p. 1604 - 1607.
Department(s) Agricultural Economics and Rural Policy Group
Publication type Refereed Article in a scientific journal
Publication year 2015
Abstract The global burden of antibiotic resistance is tremendous and, without new anti-infective strategies, will continue to increase in the coming decades. Despite the growing need for new antibiotics, few pharmaceutical companies today retain active antibacterial drug discovery programmes. One reason is that it is scientifically challenging to discover new antibiotics that are active against the antibiotic-resistant bacteria of current clinical concern. However, the main hurdle is diminishing economic incentives. Increased global calls to minimize the overuse of antibiotics, the cost of meeting regulatory requirements and the low prices of currently marketed antibiotics are strong deterrents to antibacterial drug development programmes. New economic models that create incentives for the discovery of new antibiotics and yet reconcile these incentives with responsible antibiotic use are long overdue. DRIVE-AB is a €9.4 million public–private consortium, funded by the EU Innovative Medicines Initiative, that aims to define a standard for the responsible use of antibiotics and to develop, test and recommend new economic models to incentivize investment in producing new anti-infective agents.
There are no comments yet. You can post the first one!
Post a comment
Please log in to use this service. Login as Wageningen University & Research user or guest user in upper right hand corner of this page.